Menopause

ANAHEIM, Calif. — In this video exclusive, Nanette Santoro, MD, describes paradigm shifts in understanding the menopause transition and its implications for health.

A study of women with menopause aged 45 to 60 years found that menopausal hormone therapy may reduce the odds of developing adhesive capsulitis.

ANAHEIM, Calif. — Midlife women with a history of infertility or involuntary childlessness had more depressive symptoms, particularly before menopause, and anxiety after menopause, compared with women without infertility.

Women who experienced vasomotor symptoms had elevated whole brain volume of white matter hyperintensities, which can affect brain health, data presented at the NAMS Annual Meeting showed.

Women diagnosed with type 1 diabetes before age 30 years or type 2 diabetes at age 30 to 39 years are more likely to reach menopause earlier than women without diabetes, according to study results.

Potentially perimenopausal women who took relugolix combination therapy for uterine fibroids and heavy menstrual bleeding experienced significant reductions in menstrual bleeding and fibroid-related pain vs. those who took placebo.

Women who did not receive menopausal hormone therapy had greater odds of developing adhesive capsulitis compared with those on HT, according to preliminary study results presented at the North American Menopause Society annual meeting.

Women taking fezolinetant for moderate to severe vasomotor symptoms experienced a reduction in symptom severity and sleep disturbances, according to data presented at the NAMS Annual Meeting.

Women who reported night sweats during menopause had high scores for both stress and depression, and those who reported hot flashes had elevated depression scores, according to data presented at the NAMS Annual Meeting in Atlanta.

The estrogen estetrol was associated with decreased frequency and severity of vasomotor symptoms for postmenopausal women, study findings presented at the NAMS Annual Meeting showed.